TAF Switch Study in Hepatitis B Monoinfection

• Status: Unknown status
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate various markers of renal function and bone density after the switch to Tenofovir alafenamide fumarate (TAF) in chronic hepatitis B patients who are currently treated with Tenofovir disoproxil fumarate (TDF) .

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asian Pacific Liver Center at St. Vincent Medical Center
• Treatments: Tenofovir

Criteria

Inclusion Criteria:

• Patients with chronic hepatitis B (who are either HBeAg reactive or non-reactive)

• Treated with TDF with unquantifiable Hepatitis B Virus (HBV) DNA by a sensitive Polymerase chain reaction (PCR) assay for a minimum of 6 months

• No prior nucleos(t)ide exposure prior to treatment with TDF

• Treatment with TDF for a minimum of 12 months

Exclusion Criteria:

• HIV Infection